Home LiteratureArticle Details
PMID: 18463375 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Hyperglycemia and adverse pregnancy outcomes.

The New England journal of medicine ·Vol. 358 ·No. 19 ·2008-05-08 ·Pages 1991-2002

HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA

Abstract

It is controversial whether maternal hyperglycemia less severe than that in diabetes mellitus is associated with increased risks of adverse pregnancy outcomes. A total of 25,505 pregnant women at 15 centers in nine countries underwent 75-g oral glucose-tolerance testing at 24 to 32 weeks of gestation. Data remained blinded if the fasting plasma glucose level was 105 mg per deciliter (5.8 mmol per liter) or less and the 2-hour plasma glucose level was 200 mg per deciliter (11.1 mmol per liter) or less. Primary outcomes were birth weight above the 90th percentile for gestational age, primary cesarean delivery, clinically diagnosed neonatal hypoglycemia, and cord-blood serum C-peptide level above the 90th percentile. Secondary outcomes were delivery before 37 weeks of gestation, shoulder dystocia or birth injury, need for intensive neonatal care, hyperbilirubinemia, and preeclampsia. For the 23,316 participants with blinded data, we calculated adjusted odds ratios for adverse pregnancy outcomes associated with an increase in the fasting plasma glucose level of 1 SD (6.9 mg per deciliter [0.4 mmol per liter]), an increase in the 1-hour plasma glucose level of 1 SD (30.9 mg per deciliter [1.7 mmol per liter]), and an increase in the 2-hour plasma glucose level of 1 SD (23.5 mg per deciliter [1.3 mmol per liter]). For birth weight above the 90th percentile, the odds ratios were 1.38 (95% confidence interval [CI], 1.32 to 1.44), 1.46 (1.39 to 1.53), and 1.38 (1.32 to 1.44), respectively; for cord-blood serum C-peptide level above the 90th percentile, 1.55 (95% CI, 1.47 to 1.64), 1.46 (1.38 to 1.54), and 1.37 (1.30 to 1.44); for primary cesarean delivery, 1.11 (95% CI, 1.06 to 1.15), 1.10 (1.06 to 1.15), and 1.08 (1.03 to 1.12); and for neonatal hypoglycemia, 1.08 (95% CI, 0.98 to 1.19), 1.13 (1.03 to 1.26), and 1.10 (1.00 to 1.12). There were no obvious thresholds at which risks increased. Significant associations were also observed for secondary outcomes, although these tended to be weaker. Our results indicate strong, continuous associations of maternal glucose levels below those diagnostic of diabetes with increased birth weight and increased cord-blood serum C-peptide levels.

MeSH Terms
Adult Blood Glucose/analysis C-Peptide/blood Cesarean Section/statistics & numerical data Female Fetal Blood/chemistry Fetal Macrosomia/epidemiology Glucose Tolerance Test Humans Hyperglycemia/blood,complications Hypoglycemia/epidemiology,etiology Infant, Newborn Odds Ratio Pregnancy Pregnancy Complications/blood Pregnancy Outcome
Chemicals
Blood Glucose C-Peptide
Authors & Affiliations
15 authors, click to expand affiliations / ORCID
HAPO Study Cooperative Research Group
Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. [email protected]
Metzger Boyd E
Lowe Lynn P
Dyer Alan R
Trimble Elisabeth R
Chaovarindr Udom
Coustan Donald R
Hadden David R
McCance David R
Hod Moshe
McIntyre Harold David
Oats Jeremy J N
Persson Bengt
Rogers Michael S
Sacks David A
Investigators
152 investigators, click to expand
Contreras M
Sacks D A
Watson W
Dooley S L
Foderaro M
Niznik C
Bjaloncik J
Catalano P M
Dierker L
Fox S
Gullion L
Johnson C
Lindsay C A
Makovos H
Saker F
Carpenter M W
Hunt J
Somers M H
Amankwah K S
Chan P C
Gherson B
Herer E
Kapur B
Kenshole A
Lawrence G
Matheson K
Mayes L
McLean K
Owen H
Cave C
Fenty G
Gibson E
Hennis A
McIntyre G
Rotchell Y E
Spooner C
Thomas H A R
Gluck J
Hadden D R
Halliday H
Irwin J
Kearney O
McAnee J
McCance D R
Mousavi M
Traub A I
Cruickshank J K
Derbyshire N
Dry J
Holt A C
Khan F
Lambert C
Maresh M
Prichard F
Townson C
van Haeften T W
van de Hengel A M R
Visser G H A
Zwart A
Chaovarindr U
Chotigeat U
Deerochanawong C
Panyasiri I
Sanguanpong P
Amichay D
Golan A
Marks K
Mazor M
Ronen J
Wiznitzer A
Chen R
Harel D
Hoter N
Melamed N
Pardo J
Witshner M
Yogev Y
Bowling F
Cowley D
Devenish-Meares P
Liley H G
McArdle A
McIntyre H D
Morrison B
Peacock A
Tremellen A
Tudehope D
Chan K Y
Chan N Y
Ip L W
Kong S L
Lee Y L
Li C Y
Ng K F
Ng P C
Rogers M S
Wong K W
Edgar M
Giles W
Gill A
Glover R
Lowe J
Mackenzie F
Siech K
Verma J
Wright A
Cao Y H
Chee J J
Koh A
Tan E
Rajadurai V J
Wee H Y
Yeo G S H
Coustan D
Haydon B
Alexander A
Hadden D R
Attias-Raved O
Hod M
Oats J J N
Parry A F
Collard A
Frank A S
Lowe L P
Metzger B E
Thomas A
Case T
Cholod P
Dyer A R
Engelman L
Xiao M
Yang L
Burgess C I
Lappin T R J
Nesbitt G S
Sheridan B
Smye M
Trimble E R
Dyer A R
Hod M
Metzger B E
Lowe L P
Oats J J N
Persson B
Trimble E R
Cutter G R
Gabbe S G
Hare J W
Wagenknecht L E
Chen Y
Claman J
King J
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2008-05-08
Pages
1991-2002
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Grants
NCRR NIH HHS · UL1 RR024989 · United States
NICHD NIH HHS · R01-HD34242 · United States
NCRR NIH HHS · M01-RR00048 · United States
NCRR NIH HHS · M01 RR000080 · United States
NCRR NIH HHS · M01-RR00080 · United States
NICHD NIH HHS · R01-HD34243 · United States
Corrections
CommentIn
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]